Cipro vs. Bactrim

See how Cipro and Bactrim compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Cipro carries an FDA black box warning for tendon rupture and nerve damage, while Bactrim carries no such warning but can trigger severe skin reactions and is unsafe for infants under 2 months old.

  • Cipro treats urinary, skin, bone, and respiratory infections in short 3 to 14 day courses, while Bactrim is the go-to choice for Pneumocystis pneumonia, ear infections in children, and traveler's diarrhea.

  • Both drugs are older, widely used generic antibiotics, but they come from different drug classes with different resistance patterns and side effect profiles.

Cipro vs. Bactrim Drug Summary

Cipro

Cipro (ciprofloxacin) is a fluoroquinolone antibiotic used for urinary tract, respiratory, skin, bone, and abdominal infections, plus anthrax and plague exposure. It works by blocking bacterial DNA replication and is taken as a tablet, liquid, or IV infusion, usually twice a day for 3 to 14 days depending on the infection.

Bactrim

Bactrim (sulfamethoxazole and trimethoprim) is a combination sulfonamide antibiotic used for urinary tract infections, ear infections in children, traveler's diarrhea, and Pneumocystis pneumonia. It blocks two sequential steps in bacterial folate production and is taken as a tablet, liquid, or IV infusion, usually twice a day for 5 to 21 days depending on the infection.

Cipro vs. Bactrim Side Effects

Cipro

Most common
Vomiting (up to 4.8%)
Nausea (up to 2.7%)
Rash (up to 1.8%)
Diarrhea (up to 4.8%)

Bactrim

Most common
Vomiting (rate not specified)
Nausea (rate not specified)
Rash (rate not specified)
Anorexia (rate not specified)

Cipro vs. Bactrim Dosage

Cipro

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 250 mg every 12 hours At the start
Maximum dose 750 mg every 12 hours If needed
Dose changes 2 increases As tolerated

Bactrim

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 800 mg/160 mg every 12h At the start
Maximum dose 8-10 mg/kg/day div q6-12h If needed
Dose changes 3 increases As tolerated

Cipro vs. Bactrim Indications

Cipro

Cipro is FDA-approved for a wide range of bacterial infections in adults, including complicated and uncomplicated urinary tract infections, skin and bone infections, and lower respiratory tract infections. It is also approved for infectious diarrhea, typhoid fever, and post-exposure prophylaxis for inhalational anthrax and plague.

  • Uncomplicated and complicated UTIs

  • Skin, bone, and joint infections

  • Lower respiratory tract infections

  • Inhalational anthrax and plague exposure

  • Infectious diarrhea and typhoid fever

Bactrim

Bactrim is FDA-approved to treat urinary tract infections, acute ear infections in children, and flare-ups of chronic bronchitis in adults. It is also approved for shigellosis, traveler's diarrhea, and both treatment and prevention of Pneumocystis jirovecii pneumonia.

  • Urinary tract infections

  • Acute ear infections in children

  • Chronic bronchitis flare-ups

  • Pneumocystis pneumonia treatment and prevention

  • Shigellosis and traveler's diarrhea

Cipro vs. Bactrim Pros and Cons

Cipro

Cipro's fluoroquinolone class gives it broad activity against tough Gram-negative bacteria, including Pseudomonas, and it comes in an IV form for severe infections. That same class carries an FDA black box warning for tendon, nerve, and central nervous system damage.

Pros

  • Effective against Pseudomonas and other tough Gram-negative bacteria

  • Available as IV for hospitalized or severe infections

  • Short 3-day course for uncomplicated UTIs

  • Used for anthrax and plague exposure

Cons

  • Black box warning for tendon rupture and nerve damage

  • FDA advises against use for sinusitis or bronchitis when alternatives exist

  • Can interact with antacids, tizanidine, and other common drugs

  • Risk of C. diff-associated diarrhea

Bactrim

Bactrim's combination of two antibacterial agents blocks bacterial folate production at two separate steps, giving it a niche role in Pneumocystis pneumonia and off-label MRSA skin infections. It does not carry a black box warning, but it is contraindicated in infants and in patients with certain blood or enzyme disorders.

Pros

  • No black box warning like fluoroquinolones

  • Preferred option for Pneumocystis pneumonia

  • Commonly used off-label for MRSA skin infections

  • Long track record since FDA approval in 1973

Cons

  • Contraindicated in infants under 2 months old

  • Risk of severe skin reactions like Stevens-Johnson syndrome

  • Unsafe for patients with G6PD deficiency

  • Not effective for strep throat

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.